CardioComm Collaborates with ZANA Technologies GmbH to Integrate Mobile ECG Management and Smartphone App Technologies

ECG technologies to be tested within ZANA's remote patient monitoring platform in 2020

Toronto, Ontario--(Newsfile Corp. - December 3, 2019) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company" or "CCS"), a global provider of consumer heart monitoring and electrocardiogram ("ECG") acquisition and management software solutions, and Karlsruhe, Germany-based start-up ZANA Technologies GmbH ("ZANA") confirm entering into a business collaboration where CardioComm's GEMS™ ECG reviewing and HeartCheck™ ECG monitoring technologies are being evaluated to support ZANA's novel, voice-directed, remote patient monitoring and patient management platform.

Through the use of deployable versions of the GEMS™ Mobile Smartphone, the GUAVA ECG viewer and GEMS™ ECG management software, ZANA will embed CardioComm's ECG management technologies into its mobile app and patient engagement platform. ZANA users will be able to download one Smartphone app through which ECG recordings and clinical feedback will be provided using ZANA's cloud-based patient engagement platform where CardioComm's hospital ECG management software technologies will have been incorporated.

ZANA has decided to partner with CardioComm Solutions and its HeartCheck™ CardiBeat ECG device and GEMSTM software solutions to be evaluated by multiple medical centres throughout Europe in ZANA's bid to become a preferred vendor for telemedicine solutions for monitoing a patient's post-hospital discharge. ZANA's disruptive patient enagement platform uses an intelligent, voice-/chat-based assistant with interactive and learning technologies that permit home-based, continuous health monitoring, designed to improve the health outcomes of its patients. As patient ECG monitoring requirements evolve, CardioComm will provide ZANA support in expanding the user's access to other ECG monitoring methodologies that may be requested as part of any comprehensive physician-directed hospital discharge plan. This will include the use of 12 lead ECGs and long-term continuous ECG monitoring devices.

The companies will provide updates on the clinical testing results as they become available. To learn more about CardioComm's products and for further updates regarding HeartCheck™ ECG device integrations, please visit the Company's websites at www.cardiocommsolutions.com and www.theheartcheck.com.

About CardioComm Solutions

CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm Solutions has earned the ISO 13485:2016 MDSAP certification, is HIPAA compliant and holds clearances from the European Union (CE Mark), the USA (FDA) and Canada (Health Canada).

About ZANA

Zana Technologies GmbH is an award-winning digital health start-up based in Germany that offers cutting-edge conversational AI and wearables integration for remote health monitoring. The main product offering is an intelligent voice assistant that establishes a direct bridge between patients and doctors. The innovative remote care solution is designed to improve and lower costs of post-operative and chronic care. ZANA combines active conversation in natural language with real-time monitoring through connected devices, all from the comfort of a patient's home through a Smartphone or smart home device. ZANA's backend collects and presents the monitored patient's data through an innovative dashboard system that updates doctors about their patient's health continuously and securely.

FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425 x227
egrima@cardiocommsolutions.com
investor.relations@cardiocommsolutions.com

Forward-looking statements

This release may contain certain forward-looking statements and forward-looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.

In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/50342

info